Ozempic

Overview

Ozempic (semaglutide) is a once-weekly GLP-1 receptor agonist approved for type 2 diabetes management. While not FDA-approved for weight loss, widespread off-label prescribing for weight management has made it the most publicly recognized GLP-1 medication. The SUSTAIN and PIONEER trial programs established its glycemic efficacy, while real-world and STEP trial data confirmed significant weight loss.

Mechanism of Action

Semaglutide activates the GLP-1 receptor, enhancing glucose-dependent insulin secretion, suppressing inappropriate glucagon release, slowing gastric emptying, and reducing appetite through centrally-mediated pathways. At the diabetes-indicated doses (0.5–2.0 mg), the primary therapeutic target is glycemic control with weight loss as a secondary benefit.

Clinical Evidence

The SUSTAIN trial program demonstrated superior HbA1c reduction versus comparators including sitagliptin, exenatide ER, and insulin glargine. SUSTAIN 6 showed a significant reduction in cardiovascular events. Weight loss in diabetes populations typically ranges from 4–6 kg at the 1 mg dose. When used off-label at higher doses or in non-diabetic populations, greater weight loss has been observed, though Wegovy (2.4 mg) is the approved weight-management formulation.

Side Effects & Safety

Nausea (15–20%), diarrhea, vomiting, constipation, and abdominal pain are the most common. GI side effects tend to be milder at diabetes-level doses (0.5–1.0 mg) compared to the weight-management dose (2.4 mg in Wegovy). Pancreatitis, gallbladder events, and diabetic retinopathy complications have been reported.

FAQ